OncoMatch/Clinical Trials/NCT07003568
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Is NCT07003568 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Dual-targeting BCMA-GPRC5D CAR-T cell infusion for relapsed or refractory multiple myeloma (rrmm).
Treatment: Dual-targeting BCMA-GPRC5D CAR-T cell infusion — This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - GPRC5D CAR-T cell therapy. The primary objective is to prospectively evaluate the safety of dual-targeting BCMA and GPRC5D CAR - T cell therapy for extramedullary infiltration in relapsed/refractory multiple myeloma. The primary endpoints are to assess the type and incidence of dose-limiting toxicity (DLT) within one month after the reinfusion of BCMA-GPRC5D CAR-T cells in patients, as well as the incidence and severity of adverse events within one month after the reinfusion. It is expected that no more than 18 participants will be recruited.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA positive by flow cytometry or immunohistochemistry
Positive for BCMA and GPRC5D in flow cytometry of bone marrow or cerebrospinal fluid tumor cells or immunohistochemistry of tumor tissue
Required: GPRC5D positive by flow cytometry or immunohistochemistry
Positive for BCMA and GPRC5D in flow cytometry of bone marrow or cerebrospinal fluid tumor cells or immunohistochemistry of tumor tissue
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: vector with the same structure
Previous use of a CAR - T vector with the same structure
Lab requirements
Kidney function
creatinine clearance rate ≥ 40 ml/min (by cockcroft and gault formula)
Liver function
alanine aminotransferase and aspartate aminotransferase < 3 times the upper limit of normal (uln)
Cardiac function
left ventricular ejection fraction > 50% (by echocardiogram) in the past 2 weeks
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07003568 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require BCMA?
Yes, BCMA positive by flow cytometry or immunohistochemistry is a required biomarker for enrollment.
Does this trial require GPRC5D?
Yes, GPRC5D positive by flow cytometry or immunohistochemistry is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages